

# CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Incorporated in the Republic of Singapore)  
(Company Registration No. 200505118M)

## PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – USE OF PROCEEDS FROM THE RIGHTS CUM WARRANTS ISSUE

1. The Board of Directors (“**Directors**”) of China Medical (International) Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements made by the Company on 10 November 2017 (the “**Previous Announcement**”) and the offer information statement dated 3 October 2017 (“**OIS**”) in relation to the proposed renounceable and non-underwritten rights issue of the Company (the “**Rights cum Warrants Issue**”).
2. Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the OIS.
3. On 10 November 2017, the Company announced in the Previous Announcement the use of \$1.438 million of the proceeds from the Rights cum Warrants Issue for the purposes of loan repayment and working capital in payment of professional fees and payment of other services.
4. Further to the above, the Board wishes to announce that the Company has applied the sum of S\$0.8 million, representing approximately 14.3% of the proceeds of S\$5.601 million raised from the Rights cum Warrants Issue (before the exercise of the Warrants), towards the full repayment of a third-party loan and the repayment of interest of S\$48,000 for this loan which is classified under working capital usage. An update of the use of the proceeds from the Rights cum Warrants Issue is set out below:

Use of proceeds	Allocation of proceeds raised (S\$)	Amount utilised as at 9 November 2017 (S\$)	Amount utilised from 10 November to 30 November 2017 (S\$)	Amount unutilised as at 30 November 2017 (S\$)
<b>Proceeds from 2017 Rights cum Warrants issue:</b>				
(i) Working Capital	2,801,000	238,000	48,000	2,515,000
(ii) Loan repayment	2,800,000	1,200,000	800,000	800,000
<b>Total Amount</b>	<b>5,601,000</b>	<b>1,438,000</b>	<b>848,000</b>	<b>3,315,000</b>

5. As at the date of this announcement, the Company has utilised S\$2.286 million, representing approximately 40.8% of the proceeds of S\$5.601 million raised from the Rights cum Warrants Issue (before the exercise of the Warrants).
6. The foregoing use of proceeds is in accordance with the intended uses as set out in the Previous Announcement (which sets out the re-allocation of proceeds pursuant to the undersubscription of the Rights cum Warrants Issue).
7. The Company shall continue to make periodic announcements on the use of such proceeds as and when they are materially disbursed, and will provide a status report on the use of proceeds raised from the Rights cum Warrants Issue in its interim and full-year financial statements and its annual report, until such time the proceeds have been fully utilised.

**By Order of the Board**  
**30 November 2017**

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).*